Literature DB >> 19236549

Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study.

Denis Guyonnet1, Alison Woodcock, Blandine Stefani, Cristina Trevisan, Claire Hall.   

Abstract

AIM: Some probiotics improve digestive comfort of people with Irritable Bowel Syndrome, but this needs confirmation in a healthy population. The objective of this pilot study was to investigate the effect of consuming fermented milk containing the probiotics Bifidobacterium lactis DN-173010 and yoghourt strains (test product) on digestive comfort and symptoms amongst adults without diagnosed gastrointestinal disorders.
METHODS: The study was designed to approximate a real-life situation, by using a branded product in the intervention groups. In an open-label, randomized, controlled trial, 371 adults reporting digestive discomfort were randomized into three groups who had a daily consumption of either one or two pots of test product over 2 weeks, or to follow their usual diet. Digestive comfort and bother from digestive symptoms were assessed by questionnaire at baseline and follow-up (per protocol population n = 360). Self-reported change in digestive comfort and computed change between baseline and follow-up for each of 20 items were compared between groups (Cochran-Mantel-Haenszel test).
RESULTS: A higher percentage of participants consuming the test product reported improved digestive comfort (1-pot group 82.5%; 2-pot group 84.3%), than controls (2.9%). Their self-reported change scores differed significantly (P < 0.001). For both test product groups, almost all symptom scores improved significantly more than controls (P < 0.001). There were no significant differences between 1-pot and 2-pot groups.
CONCLUSIONS: This pilot study shows that daily consumption of a probiotic food in real-life conditions may be useful in improving digestive comfort and symptom experience of adults from general population. Further double-blind randomized controlled studies are required to confirm these health benefits.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236549     DOI: 10.1111/j.1751-2980.2008.00366.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  11 in total

1.  Bifidobacterium animalis subsp. lactis ATCC 27673 is a genomically unique strain within its conserved subspecies.

Authors:  Joseph R Loquasto; Rodolphe Barrangou; Edward G Dudley; Buffy Stahl; Chun Chen; Robert F Roberts
Journal:  Appl Environ Microbiol       Date:  2013-08-30       Impact factor: 4.792

Review 2.  Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population.

Authors:  Jacqui Eales; Peter Gibson; Peter Whorwell; John Kellow; Ann Yellowlees; Richard H J Perry; Mary Edwards; Sarah King; Hannah Wood; Julie Glanville
Journal:  Therap Adv Gastroenterol       Date:  2016-10-10       Impact factor: 4.409

3.  Consumption of fermented milk product with probiotic modulates brain activity.

Authors:  Kirsten Tillisch; Jennifer Labus; Lisa Kilpatrick; Zhiguo Jiang; Jean Stains; Bahar Ebrat; Denis Guyonnet; Sophie Legrain-Raspaud; Beatrice Trotin; Bruce Naliboff; Emeran A Mayer
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

4.  Treatment of irritable bowel syndrome with probiotics: growing evidence.

Authors:  Miguel Bixquert
Journal:  Indian J Med Res       Date:  2013       Impact factor: 2.375

5.  Personal relative deprivation associated with functional disorders via stress: An examination of fibromyalgia and gastrointestinal symptoms.

Authors:  Shadi Beshai; Sanju Mishra; Sandeep Mishra; R Nicholas Carleton
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

6.  A Fermented Milk Product with B. Lactis CNCM I-2494 and Lactic Acid Bacteria Improves Gastrointestinal Comfort in Response to a Challenge Diet Rich in Fermentable Residues in Healthy Subjects.

Authors:  Boris Le Nevé; Adrian Martinez de la Torre; Julien Tap; Muriel Derrien; Aurélie Cotillard; Elizabeth Barba; Marianela Mego; Adoración Nieto Ruiz; Laura Hernandez-Palet; Quentin Dornic; Jean-Michel Faurie; John Butler; Xavi Merino; Beatriz Lobo; Ferran Pinsach Batet; Anna Accarino; Marta Pozuelo; Chaysavanh Manichanh; Fernando Azpiroz
Journal:  Nutrients       Date:  2020-01-25       Impact factor: 5.717

7.  A Fermented Milk Product Containing B. lactis CNCM I-2494 Improves the Tolerance of a Plant-Based Diet in Patients with Disorders of Gut-Brain Interactions.

Authors:  Boris Le Nevé; Adrian Martinez-De la Torre; Julien Tap; Adoración Nieto Ruiz; Muriel Derrien; Aurélie Cotillard; Jean-Michel Faurie; Elizabeth Barba; Marianela Mego; Quentin Dornic; John Butler; Xavi Merino; Beatriz Lobo; Ferran Pinsach Batet; Marta Pozuelo; Javier Santos; Francisco Guarner; Chaysavanh Manichanh; Fernando Azpiroz
Journal:  Nutrients       Date:  2021-12-18       Impact factor: 5.717

Review 8.  Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review.

Authors:  Jing Cheng; Arja Laitila; Arthur C Ouwehand
Journal:  Front Nutr       Date:  2021-12-14

9.  Human gut metatranscriptome changes induced by a fermented milk product are associated with improved tolerance to a flatulogenic diet.

Authors:  Iñigo Oyarzun; Boris Le Nevé; Francisca Yañez; Zixuan Xie; Matthieu Pichaud; Gerard Serrano-Gómez; Joaquim Roca; Patrick Veiga; Fernando Azpiroz; Julien Tap; Chaysavanh Manichanh
Journal:  Comput Struct Biotechnol J       Date:  2022-04-05       Impact factor: 6.155

10.  Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice.

Authors:  Rebeca Martín; Laure Laval; Florian Chain; Sylvie Miquel; Jane Natividad; Claire Cherbuy; Harry Sokol; Elena F Verdu; Johan van Hylckama Vlieg; Luis G Bermudez-Humaran; Tamara Smokvina; Philippe Langella
Journal:  Front Microbiol       Date:  2016-05-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.